文献速递肝病

真实世界队列中血浆置换未改善急性肝衰竭患者的总生存率

Plasma exchange does not improve overall survival in patients with acute liver failure in a real-world cohort.
PubMed 文献 · J Hepatol · 2024-10-01

这项多中心回顾性队列研究纳入英国七家肝移植中心2013年6月至2021年12月的378例急性肝衰竭患者,其中120例接受血浆置换。血浆置换后多数临床指标显著改善,包括去甲肾上腺素中位剂量下降,但倾向性评分匹配后,血浆置换组与标准药物治疗组在总生存率和无移植生存率上均无显著差异。

要点

  • 英国真实世界中血浆置换已常用于急性肝衰竭,但未显示生存获益。
  • 血浆置换后去甲肾上腺素中位剂量从0.35 μg/kg/min降至0.16 μg/kg/min(p=0.001)。
  • 血浆置换组与标准药物治疗组总生存率51.4% vs 62.6%,无显著差异(p=0.12)。

核心结论

  • 血浆置换在英国急性肝衰竭管理中已被频繁使用,与血流动力学参数显著改善相关,但未带来生存获益。
  • 该真实世界研究未证实既往文献中观察到的血浆置换生存获益。

研究设计与样本

  • 多中心回顾性队列研究,纳入英国全部七家三级肝移植中心2013年6月至2021年12月连续收治的急性肝衰竭患者。
  • 共纳入378例患者,中位年龄36岁(IQR 28-48),女性64%(n=242),其中120例接受血浆置换。
  • 采用倾向性评分匹配控制组间协变量和选择偏倚,比较血浆置换组与标准药物治疗组的至出院总生存率和无移植生存率。

主要发现

  • 血浆置换后多数临床指标显著改善,去甲肾上腺素中位剂量从0.35 μg/kg/min(IQR 0.19-0.70)降至0.16 μg/kg/min(IQR 0.08-0.49),p=0.001。
  • 血浆置换组与标准药物治疗组总生存率分别为51.4%和62.6%,差异无统计学意义(p=0.12)。
  • 血浆置换组与标准药物治疗组无移植生存率分别为42.6%和53.1%,差异无统计学意义(p=0.24)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Therapeutic plasma exchange (PEX) has emerged as a potential treatment option for patients with acute liver failure (ALF). The effect of PEX on survival outcomes outside of clinical trials is not yet well established. In this study we aimed to evaluate the real-world use and outcomes of PEX for the treatment of ALF. METHODS: This multicentre retrospective cohort study included consecutive patients with ALF admitted to all seven tertiary liver transplant centres in the UK between June 2013 and December 2021. Changes in clinical variables following PEX treatment were assessed, while overall survival and transplant-free survival up to hospital discharge in patients receiving PEX were compared to those receiving standard medical therapy Propensity score matching was performed to control for intergroup covariates and selection bias. RESULTS: We included 378 patients with ALF (median [IQR] age 36 (28-48), 64% [n = 242] female) of whom 120 received PEX. There was a significant improvement in most clinical variables following PEX, including median dose of noradrenaline (reduction from 0.35 μg/kg/min [0.19-0.70 μg/kg/min] to 0.16 μg/kg/min [0.08-0.49], p = 0.001). There was no significant difference between PEX and standard medical therapy groups in overall survival (51.4% vs. 62.6%, respectively, p = 0.12) or transplant-free survival (42.6% vs. 53.1%, p = 0.24). CONCLUSION: PEX is now frequently used in the management of patients with ALF in the UK. It is associated with significant improvement in haemodynamic parameters but not survival benefit. IMPACT AND IMPLICATIONS: Therapeutic plasma exchange is frequently used in the management of patients with acute liver failure in the UK. This real-world study demonstrates significant improvement in haemodynamic status but has not confirmed the survival benefit seen in previous published literature. These results should help guide the future use of plasma exchange in this patient population.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Burke L, Bernal W, Pirani T, et al. Plasma exchange does not improve overall survival in patients with acute liver failure in a real-world cohort. J Hepatol. 2024. PMID: 39362282. doi:10.1016/j.jhep.2024.09.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。